# FDA Said Yes. MHRA Said Yes. EMA Said No. - Date: 2026-04-24 - Category: Biotech & Life Sciences Three regulators examined the same cancer drug data. One said the benefit was clear. Two said it was not enough. The reason a 60% patient crossover rate confounded the survival analysis is now reshaping how companies think about building radiopharma infrastructure in Europe. ---